PharmaTimes have reported that Allergan’s Botox is now licensed in the UK for patients who have continence issues because of multiple sclerosis or a spinal injury.
The Medicines and Healthcare products Regulatory Agency has give Allergan permission to use Botox (botulinum toxin type A) for managing urinary incontinence caused by neurogenic detrusor overactivity due to subcervical spinal cord injury or multiple sclerosis (MS),
Professor Christopher Chapple, Urology Department, Royal Hallamshire Hospital, Sheffield NHS Trust and a key investigator in the neurogenic detrusor overactivity registration trials, has welcomed the new license, noting that “being able to better control and manage bladder function can be life-changing for patients”.
